Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria L Amaya

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Blood|November 14, 2025
Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulationTianyi Ling, Cristiana O'Brien, Jonathan St-Germain, et al.
Cancer Discovery|January 25, 2020
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaShanshan Pei, Daniel A Pollyea, Annika Gustafson, et al.
Blood Cancer Discovery|May 21, 2025
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN studyCurtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena, et al.
Blood Cancer Journal|June 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE databaseJan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, et al.
Nature Genetics|October 4, 2024
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemiaAndrew Stiff, Maarten Fornerod, Bailee N Kain, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Blood|November 14, 2025
Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulationTianyi Ling, Cristiana O'Brien, Jonathan St-Germain, et al.
Cancer Discovery|January 25, 2020
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaShanshan Pei, Daniel A Pollyea, Annika Gustafson, et al.
Blood Cancer Discovery|May 21, 2025
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN studyCurtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena, et al.
Blood Cancer Journal|June 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE databaseJan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, et al.
Nature Genetics|October 4, 2024
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemiaAndrew Stiff, Maarten Fornerod, Bailee N Kain, et al.
Pageof 2